My Own Specific Treatment : A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with progressive locally-advanced or metastatic solid tumors
Prospective biobanking study in ovarian, breast and head and neck cancer patients aiming at better understand the link between the molecular alterations of the tumor itself, its microenvironment and immune response.
A Phase 2, Multicenter, Open-Label Study of Entrectinib for the Treatment of Locally Advanced or Metastatic NSCLC in Adult Patients with Tumors That Harbor NTRK1, NTRK2, NTRK3 or ROS1 Molecular Alterations
A randomized, double·blind, placebo·controlled Phase III study of ODM·201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone·sensitive prostate cancer.
A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD).
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
A Prospective Randomised Phase III Study of Androgen Deprivation Therapy (+/- Docetaxel) With or Without Local Radiotherapy With or Without Abiraterone Acetate and Prednisone in Patient With Metastatic Hormone-naïve Prostate Cancer.